What is Cadrenal Therapeutics, Inc. Common Stock?
operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 7.01M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 1986,561 shares $327k | 0 |
| 6-9months | 11,165 shares $7k | 0 |
| 9-12months | 0 | 0 |